- CureToday.com
- OncLive.com
- TargetedOnc.com
- CancerNetwork.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Kristi Rosa | Authors
Articles
Antitumor Effects Noted With Infigratinib in FGFR2+ Cholangiocarcinomas Refractory to Chemotherapy
January 21, 2021
Encouraging efficacy and safety outcomes were reported at the 2021 Gastrointestinal Cancers Symposium when infigratinib was used to treat FGFR2 fusion–positive cholangiocarcinomas that are refractory to chemotherapy.
Sacituzumab Govitecan Prompts Clinical Benefit in Metastatic TNBC, Regardless of Trop-2 Expression
December 11, 2020
Sacituzumab govitecan (Trodelvy) induced clinical benefit over physician’s choice of therapy in patients with metastatic triple-negative breast cancer, irrespective of Trop-2 expression, though greater efficacy was observed in those who had a medium or high Trop-2 score.
Significant Survival Benefit Found with Ribociclib to Treat HR+/HER2- Breast Cancer
December 10, 2020
Ribociclib plus endocrine therapy continued to show a significant overall survival improvement, while delaying subsequent chemotherapy for patients with HR+/HER2-negative breast cancer.
Follow-up CTC May Predict OS in Patients with Metastatic Breast Cancer
December 09, 2020
The use of serial circulating tumor cell enumeration was confirmed to strongly predict overall survival outcomes in patients with metastatic breast cancer.
Hematologic Cancers Bear Increased Risk for Adverse COVID-19 Outcomes
December 08, 2020
Patients with hematologic malignancies were found to be at increased risk for significant morbidity and mortality from COVID-19, and the risk of death appeared to be greatest in those who were older, had more severe infection, a poorer prognosis, or who decided to forego intensive treatment.
SY-1425, Azacitidine Combo Demonstrates Clinical Activity in Heavily Pretreated R/R AML
December 08, 2020
A phase 2 trial found that SY-1425 and azacitidine demonstrated clinical activity with acceptable tolerability in a heavily pretreated population of patients with relapsed/refractory acute myeloid leukemia with RARA positivity.
Talquetamab Shows Strong Safety and Efficacy Profile When Treating Patients with Heavily Pretreated Myeloma
December 07, 2020
Data presented at the 2020 ASH Meeting found talquetamab elicited a high response rate with a tolerable safety profile for patients with relapsed/refractory multiple myeloma.
Cevostamab Monotherapy Demonstrates Manageable Safety Profile for Heavily Pretreated Relapsed/Refractory Myeloma
December 07, 2020
Cevostamab, a FcRH5xCD3 bispecific antibody, was safe and highly active when treating heavily pretreated patients with relapsed/refractory multiple myeloma, according to data presented at the 2020 ASH Annual Meeting & Exposition.
Ide-Cel Improves HRQoL in Triple-Class Exposed Relapsed/Refractory Myeloma
December 07, 2020
Idecabtagene vicleucel yielded a clinically meaningful improvements in the quality-of-life of triple-class exposed patients with relapsed/refractory multiple myeloma.
Atezolizumab Plus Bevacizumab/Chemo Does Not Significantly Improve PFS for Ovarian Cancer
September 26, 2020
The phase 3 IMagyn050/GOG 3015/ENGOT-OV39 trial indicated that the addition of atezolizumab to bevacizumab and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.